Browsing by Subject Prostate cancer

Jump to a point in the index:
Showing results 1 to 15 of 15
PreviewIssue DateTitle
-2007Bone morphogenetic proteins and their receptor signaling in prostate cancer
336781-Texto del artículo-1225051-1-10-20190219.pdf.jpg2019Cáncer de próstata: conocimientos e interferencias enla promoción y prevención de la enfermedad
Cell proliferation and apoptosis in prostate cancer. significance in disease progression and therapy.pdf.jpg2000Cell proliferation and apoptosis in prostate cancer. significance in disease progression and therapy
-2013Dendritic and lymphocytic cell infiltration in prostate carcinoma
-2010Diagnostic and prognostic value of T-cell receptor gamma alternative reading frame protein (TARP) expression in prostate cancer
Etoposide sensitivity of human prostatic cancer cell lines PC3 DU 145 and LNCaP.pdf.jpg1999Etoposide sensitivity of human prostatic cancer cell lines PC-3, DU 145 and LNCaP
Grading of the prostate carcinoma cytohistological correlations on 100 cases.pdf.jpg1986Grading of the prostate carcinoma, cyto-histological correlations on 100 cases
Hepatocyte growth factor scatter.pdf.jpg2005Hepatocyte growth factor/scatter factor and prostate cancer: a review
-2014Insight into the heterogeneity of prostate cancer through PSA-PSMA prostate clones: mechanisms and consequences
Molecular therapeutics in prostate cancer.pdf.jpg2003Molecular therapeutics in prostate cancer
-2004Neuropeptides, apoptosis and ion changes in prostate cancer. Methods of study and recent developments
Fernandez-Martinez-27-1093-1101-2012.pdf.jpg2012Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance
-2014Prognostic impact of NDRG2 and NDRG3 in prostate cancer patients undergoing radical prostatectomy
-2008SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation
-2006Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues